KONEXElectrical Equipment402420

Calth

₩1,750▼ 2.78%2026-10-02 close

Market Cap

₩4.1B

Turnover

₩190,350

Volume

113 shares

Shares out.

2.4M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

ICP-Based POC Diagnostics: At the Commercialization Crossroads

CALTH (402420) is a KONEX-listed in vitro diagnostics startup with a proprietary ICP-based point-of-care platform; while its technology is differentiated, early-stage commercialization risks—including near-zero market cap, minimal liquidity, and declining headcount—remain prominent.

1
Core technology: Proprietary ICP-based 'Nanotrap' platform combined with deep learning analytics enables high-sensitivity diagnostics superior to conventional rapid tests
2
Product portfolio: 4th-class immunodiagnostic devices including HIV1/2, HCV, HBsAg kits; POCT, self-testing, and precision diagnostics; KGMP certified manufacturing
3
Severe price correction: Current price of KRW 1,500 represents an approximately 87.5% decline from the 52-week high of KRW 12,000, reflecting the high volatility inherent in KONEX micro-cap stocks
4
Capital structure: Confirmed Series A fundraising (KRW 2.2 bn) and private convertible bond issuance (~KRW 2.3 bn), a typical financing pattern for small KONEX bioventures
5
Headcount: 26 employees as of June 2025, down 13% YoY, indicating organizational downsizing amid early-stage business operations

Business structure

CALTH builds its business around the ICP (Ion Concentration Polarization) platform 'Nanotrap' combined with deep learning analytics, offering a multi-tier product lineup spanning point-of-care testing (POCT), self-testing, and precision diagnostics.

Its flagship products are 4th-class IVD immunodiagnostic devices for infectious disease detection—including HIV1/2, HCV (hepatitis C virus), and HBsAg (hepatitis B surface antigen)—which fall under the most stringent regulatory category of the Korean Ministry of Food and Drug Safety.

On the manufacturing side, the company operates its headquarters in Seongnam, Gyeonggi-do, and a second factory in Dangjong-dong, Gunpo, Gyeonggi-do; it holds a KGMP (Korea Good Manufacturing Practice) certification, underpinning its quality management infrastructure.

Revenue is primarily derived from diagnostic device and kit sales, with platform-based new assay expansion serving as the stated pathway for future diversification.

Competitive peers in the domestic small-cap IVD space include Interloid, CareforYou, JetBiotech, and Chromah; globally, the company faces indirect competition from large IVD players such as Abbott, Roche, and SD Biosensor.

CALTH differentiates ICP technology by claiming superior sensitivity and specificity versus conventional lateral flow immunochromatography, targeting infectious disease diagnostics in resource-limited settings.

As of June 2025, the company employs 26 people—down 13% YoY—reflecting either operational streamlining or cost-reduction measures during the commercialization phase.

The patent portfolio stood at 10 registered patents as of the most recently confirmed date, forming a foundational technology moat albeit modest compared to larger industry peers.

Recent trends

As of June 7, 2026, CALTH's share price stands at KRW 1,500, up 7.22% on the day; however, this remains roughly 87.5% below the 52-week high of KRW 12,000 per Hankyung data, indicating substantial medium-to-long-term price erosion.

Daily turnover of only KRW 15,500 implies effectively non-existent trading on many sessions, a function of KONEX's structurally thin liquidity combined with a near-zero market capitalization. The company's market cap rounds to 0.0 trillion KRW, confirming its status as a nano-cap early-stage issuer.

The share price spiked to KRW 12,000 at some point in the past 52 weeks before a steep correction back to the current KRW 1,500 range.

Regarding financial results, specific revenue and operating income figures from confirmed DART filings were not accessible at the time of this report's preparation, precluding precise quantitative commentary.

That said, confirmed external fundraising history—a Series A of approximately KRW 2.2 billion and a private convertible bond issuance of approximately KRW 2.3 billion—suggests the company has yet to achieve self-sustaining operating cash flows.

The 13% YoY decline in headcount further implies active cost rationalization is underway. Industry-wide, the rapid diagnostics market has been undergoing structural normalization post-COVID-19, with many small IVD companies facing sustained profitability headwinds amid softened demand.

In summary, both the share price trajectory and the financial structure point to a period of elevated uncertainty rather than stability at this juncture.

Outlook

CALTH's growth trajectory hinges primarily on the commercial validation of its ICP-based Nanotrap platform.

The global POCT market continues to offer structural long-term demand—driven by infectious disease management in low-resource settings and chronic disease monitoring—making high-sensitivity, low-cost rapid diagnostics a viable niche.

The company's 4th-class IVD product clearances in Korea can serve as a regulatory reference for overseas market authorizations, but confirmed export revenue figures are not publicly available, leaving international commercial visibility limited.

Given the lean workforce of 26 and the reliance on external funding, achieving a sustainable break-even point on core products likely takes precedence over aggressive market expansion in the near term.

National R&D project participation remains a potentially valuable lever for technology development cost reduction and market credibility, though confirmation of specific programs is constrained by available public data.

Over the medium to long term, expanding the diagnostic assay menu on the existing platform and securing overseas distribution partnerships are likely to be the key catalysts for value realization.

Bull factors

Proprietary ICP Platform Scalability

ICP-based Nanotrap technology is understood to deliver higher sensitivity than conventional lateral flow immunochromatography, forming the company's core technological moat. Expanding the assay menu onto the same platform should yield significant R&D leverage.

The integration of deep learning analytics extends the product scope beyond simple rapid test kits into precision diagnostics, broadening the addressable market. A portfolio of over 10 registered patents provides a foundational layer of IP protection.

Structural Growth in Global POCT Demand

The global POCT market is expected to grow structurally over the medium to long term, driven by infectious disease diagnostics demand, need for affordable tests in low-resource settings, and expanding chronic disease monitoring.

CALTH's target indications—HIV and hepatitis diagnostics—are policy-supported categories backed by the WHO and national health ministries, providing a pathway to stable public procurement channels.

High-sensitivity, low-cost POCT solutions hold particularly significant demand potential in low- and middle-income countries (LMICs).

KGMP Certification as Regulatory Barrier

CALTH holds a KGMP (Korea Good Manufacturing Practice) certificate, meeting the highest domestic quality standards required for manufacturing 4th-class high-risk IVD devices.

This certification serves as credible evidence of manufacturing capability in international negotiations with buyers and distribution partners, strengthening the company's export bargaining position.

The operation of a second factory in Gunpo, Gyeonggi-do, provides production scalability to accommodate potential growth in order volumes.

Bear factors

Structural Vulnerability: Nano-Cap with Near-Zero Liquidity

A daily trading volume of KRW 15,500 effectively signals a non-functioning secondary market, which—combined with KONEX's structurally thin liquidity—distorts price discovery.

The precipitous decline from the 52-week high of KRW 12,000 to the current KRW 1,500 reflects a market structure where price is determined by sparse, episodic transactions.

Institutional and foreign investor access to KONEX nano-caps is inherently constrained, leaving virtually no stabilizing mechanism; potential equity dilution from convertible bond conversions adds further downside pressure.

Financial Sustainability Uncertainty

The confirmed funding history—Series A of KRW 2.2 billion and convertible bond issuance of approximately KRW 2.3 billion—implies limited self-sustaining operating cash flow and a persistent need for external financing.

While specific deficit figures and cash burn rates are difficult to verify from available public data, the typical profile of early-stage bioventures suggests suboptimal capital efficiency.

The 13% YoY reduction in headcount represents a cost-containment effort, but risks concurrently weakening R&D and sales execution capacity.

Lack of Visibility into Commercial Traction

Revenue figures for 2024 are available only through paid databases, making it difficult to assess commercialization progress from public information.

The in vitro diagnostics industry has broadly experienced demand normalization post-COVID-19, raising uncertainty about whether new assay launches can offset any revenue gap.

The absence of publicly disclosed customer or distribution partner agreements makes it challenging to externally verify sales momentum and pipeline maturity.

Risk factors

Regulatory Risk

Fourth-class IVD devices are subject to the most stringent regulatory scrutiny by Korea's MFDS, and obtaining clearance for new assay additions entails demanding clinical data requirements and potentially lengthy review periods.

Entry into overseas markets requires compliance with jurisdiction-specific IVD regulations—such as EU IVDR or U.S. FDA 510(k)—imposing significant time and cost burdens on market expansion plans. Regulatory changes or approval delays could directly disrupt product launch timelines and revenue forecasts.

Competitive Risk

The global IVD market is dominated by large multinationals—Abbott, Roche, Bio-Rad—and domestically, mid-cap players like SD Biosensor and Sugentech possess scale-driven cost advantages.

The HIV and hepatitis rapid diagnostic segment that CALTH targets is already well populated with established competitors, requiring substantial marketing and sales resources to translate technical superiority into commercial market share.

The company's startup-level sales infrastructure versus the capital strength and global distribution networks of larger rivals represents a structural constraint on near-term market penetration.

Macro and Market Liquidity Risk

KONEX's structurally thin liquidity can amplify additional share price declines in the event of macroeconomic shocks, rising interest rates, or deteriorating investor sentiment.

Conversion of outstanding convertible bonds into shares poses meaningful dilution risk at the current near-zero market cap level, directly eroding existing shareholder value.

A reduction in global public health budgets or diminished infectious disease policy urgency could curtail demand for diagnostics in LMIC markets, exposing the vulnerability of a public procurement-dependent revenue model.

Overall view

CALTH is an early-stage KONEX-listed bioventure with a technologically differentiated ICP-based Nanotrap platform in the in vitro diagnostics space. However, a cautious analytical stance is warranted at this juncture given multiple significant constraints.

The near-zero daily trading turnover of KRW 15,500, a share price approximately 88% below its 52-week peak, declining employee count, and a dearth of verifiable public financial disclosures collectively indicate simultaneous information asymmetry and market dysfunction.

While the long-term potential of the technology platform cannot be dismissed, commercial traction visibility is currently minimal and independent verification of financial sustainability is constrained.

Key milestones to monitor include new product regulatory clearances, disclosure of overseas distribution partnerships, and confirmed revenue growth figures; such disclosures, when they materialize, may provide a basis for reassessment.

This report is prepared for informational purposes only and does not constitute a recommendation to buy, sell, or hold any security.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 9 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.